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 Synopsis 
Objectives. The aim of this study was to characterize the population pharmacokinetics of 
piperacillin and tazobactam in critically ill infants and children, in order to develop an 
evidence-based dosing regimen. 
Patients and Methods. This pharmacokinetic study enrolled patients admitted to the paediatric 
ICU for whom intravenous piperacillin/tazobactam (8:1 ratio) was indicated (75 mg/kg q6h 
based on piperacillin). Piperacillin/tazobactam concentrations were measured by a liquid 
chromatography-tandem mass spectrometry method. Pharmacokinetic data was analysed using 
nonlinear mixed effects modelling. 
Results.  Piperacillin and  tazobactam blood samples were collected from 47 patients (median 
age: 2.83 years; range: 2 months - 15 years). Piperacillin and tazobactam disposition was best 
described by a two-compartment model which included allometric scaling and a maturation 
function to account for the effect of growth and age. Mean clearance estimates for piperacillin 
and tazobactam were 4.00 L/h and 3.01 L/h for a child of 14 kg. Monte Carlo simulations 
showed that an intermittent infusion of 75 mg/kg (based on piperacillin) q4h over 2 hours, 100 
mg/kg q4h given over 1 hour or a loading dose of 75 mg/kg followed by a continuous infusion 
of 300 mg/kg/24h were minimally required to achieve the therapeutic targets for piperacillin 
(60 % fT>MIC>16 mg/L).  
Conclusion. Standard intermittent dosing regimens do not ensure optimal 
piperacillin/tazobactam exposure in critically ill patients, thereby risking treatment failure. The 
use of a loading dose followed by a continuous infusion is recommended for treatment of severe 
infections in children >2 months of age. 
 
 
 
 INTRODUCTION 
Paediatric sepsis and septic shock reportedly affect 30% of children admitted to paediatric ICU, 
with a 25% mortality rate.1 Early intervention with appropriate antibiotic treatment remains a 
cornerstone in the pharmacological treatment of those children. 
Piperacillin/tazobactam is a broad-spectrum β-lactam antibiotic commonly used in the 
paediatric ICU for (empirical) treatment of severe infections. Typical indications include 
ventilator-associated pneumonia, intra-abdominal infections and sepsis of unknown origin. 
Despite its use, only treatment of intra-abdominal infections in children older than 2 years is 
currently approved by the European Medicines Agency.2 This means that clinical practice still 
represents off-label use of this drug combination in younger paediatric patients. 
It is well known that the efficacy of β-lactam antibiotics most strongly relates to the 
time during which the unbound drug concentration (fT) is above the pathogen MIC of the 
pathogen. The target pharmacokinetic/pharmacodynamics (PK/PD) index (i.e. fT>MIC) 
associated with positive clinical outcomes for β-lactams in critically ill patients is a fT>MIC 
between 50% to 100% of the dosing interval.3 Recent studies reported the PK/PD efficacy 
index for the β-lactamase inhibitor (BLI) tazobactam to be the percentage of time during which 
the unbound concentration remains above a threshold concentration (fT>CT).
4,5 fT>CT targets 
ranged from 35 to 85% of the dosing interval, depending on the antibiotic-BLI combination 
and stability of the β-lactamase. Threshold concentration targets were thought to depend on β-
lactamase transcription level, with upper limits of 4 mg/L used.5,6  
Piperacillin and tazobactam are predominantly excreted in unchanged form by 
glomerular filtration and tubular secretion (piperacillin: 46 to 73%; tazobactam: 65 to 80%).7 
In addition, saturable renal elimination has been identified previously in adults.8–10 To date, the 
pharmacokinetics of piperacillin/tazobactam have been described in (pre)term neonates and 
non-ICU children, but only in a small number of children admitted to the paediatric ICU (n=13 
 and n=12 patients), between 1 and 9 years of age.7,11–15 
Any effort to define the dose rationale in infants and young children needs to account for the 
effect of developmental processes, which are known to affect drug exposure and potentially 
treatment response.16 Moreover, the impact of pathophysiological changes on 
pharmacokinetics has been widely demonstrated in critically ill adults.17–19  The aims of this 
study were therefore (i) to investigate the pharmacokinetics of intravenous piperacillin and 
tazobactam in critically ill infants and children, and (ii) to revisit the dose rationale of the drug 
combination and evaluate the efficacy of current and alternative dosing regimens in this 
population based on PK/PD indices.  
 
PATIENTS AND METHODS 
Study design and ethics 
A prospective, pharmacokinetic study was conducted at the paediatric ICU unit of the Ghent 
University Hospital, Ghent, Belgium between May 2012 and March 2014. Patients between 1 
month and 15 years of age admitted to the paediatric ICU in whom treatment with intravenous 
piperacillin/tazobactam was clinically indicated, were included. Patients were excluded if they 
required an extracorporeal circuit or did not have, other than the drug infusion line, an arterial 
or intravenous access available for blood sampling. The research was conducted in accordance 
with the guidelines of the Declaration of Helsinki, was approved by the institutional Ethics 
Committee (EC/2012/172) and was registered at Clinicaltrials.gov (NCT02456974). Written 
informed consent was obtained from the parents or legal representatives as well as assent from 
patients older than 12 years. Collected demographic and clinical variables included: body 
weight (WT), postmenstrual age (PMA), primary reason for admission, measures of organ 
function and patient severity of illness as described by the PELOD (Pediatric Logistic Organ 
Dysfunction) Score, PRISM II (Pediatric Risk of Mortality) Score, type of catheter used for 
 drug administration and blood sampling, presence of mechanical ventilation, co-treatment with 
vasopressors and nephrotoxic medications (amikacin, ibuprofen, diclofenac, vancomycin, 
teicoplanin), presence of surgery, fluid resuscitation (>60 mL/kg per 24 hour), and C-Reactive 
Protein (CRP).20,21 
Drug dosing and administration 
Piperacillin/tazobactam (Tazocin® 2 g/250 mg and Tazocin® 4 g/500 mg, Pfizer, Belgium)  was 
prescribed in a dose of 75 mg piperacillin per kilogram body weight (maximum 4000 mg) every 
6 hours and administered intravenously over 5 to 30 minutes using a calibrated syringe driver, 
according to current dosing guidelines.22 Immediately after drug administration, infusion lines 
were flushed with normal saline with a minimum of twice the dead space volume. 
Blood sampling 
Serial blood samples were obtained from 1st and/or assumed steady-state doses from an 
indwelling catheter other than the drug infusion line. The total number of samples collected 
(per individual patient) was limited by the predefined total maximum blood volume permitted 
for PK sampling (i.e. 2.4 mL/kg body weight).23 A typical sampling scheme included blood 
sampling just before dosing (t=0), immediately after dosing and flush, between 5  and 70 min 
after the start of the infusion, at 3 hours after the start of the infusion and a trough sample just 
prior to the next dose. All samples were immediately transferred on ice to the chemistry 
laboratory and centrifuged (8 minutes, 1885g) after which the resulting plasma was frozen at -
80°C for a maximum of 3 months before assay.   
Drug and biochemical assays  
Piperacillin and tazobactam total plasma concentrations were quantified simultaneously using 
a validated UPLC-tandem mass spectrometry method.24 The lower limit of quantification 
(LLOQ) was 0.5 mg/L for both compounds and the imprecision was < 15% at all levels. For 
the first 29 patients, only the piperacillin compound was quantified. Plasma Cystatin C (CysC) 
 was measured using the N Latex cystatin C assay on the Behring Nephelometer II (Siemens 
Healthcare Diagnostics Products GmbH, Marburg, Germany) (intra-assay coefficient of 
variation [CV]: 1.4%; inter-assay CV: 5.4%) and was standardized according to the ERM-
DA471/IFCC reference material.25 Creatinine was measured in serum (Scr) using the rate-
blanked compensated Jaffe technique (Modular P and Cobas 6000, Roche Diagnostics GmbH, 
Mannheim, Germany).  
Pharmacokinetic analysis 
The pharmacokinetics of piperacillin/tazobactam was evaluated using non-linear mixed effects 
modelling. Data were analysed using the first-order conditional estimation method with the 
interaction option (FOCE-I), as implemented in NONMEM version 7.2 (ICON PLC; Ellicott 
City, Maryland). R (version 3.1.1) and PsN (version 3.5.3) were used for pre- and post-
processing of the data as well as the creation of graphical and statistical summaries. One-, two-
, and three-compartment disposition models with zero order input were tested to  characterize 
the time course of plasma concentrations of both compounds independently using the ADVAN 
subroutines.26 For piperacillin, first-order (FO), Michaelis-Menten (MM) and FO+MM 
elimination were also evaluated.  A decrease in objective function value (OFV) of 3.84 points 
(p<0.05) or more was considered statistically significant assuming a χ2 distribution for nested 
models. Goodness-of-fit included visual inspection of the following plots: observed versus 
population predicted concentrations, observed versus individual predicted concentrations, 
conditional weighted residuals versus time, conditional weighted residuals versus population 
predicted concentrations.  
  A log-normal distribution was assumed for the between-subject variability (BSV), 
whereas additive and proportional models (and a combination of both) were tested to describe 
residual variability in the data. Interoccasion variability (IOV) was tested on clearance and 
central volume of distribution of piperacillin. 
  Covariate model building 
Continuous covariates were evaluated using a linear or exponential equation (equation 1): 
 
𝑃𝑖 = 𝑃𝑝𝑜𝑝 × (
𝐶𝑂𝑉
𝑚𝑒𝑑𝑖𝑎𝑛 (𝐶𝑂𝑉)
)
𝑘
(1) 
 
In this equation 𝑃𝑖 represents the individual parameter estimate of the ith subject, 𝑃𝑝𝑜𝑝 
represents the population parameter estimate, COV is the covariate of interest and k the 
exponent which is fixed to 1 for a linear function and estimated for an exponential function. 
Binary covariates were tested using the following equation (equation 2): 
 
𝑃𝑖 = 𝑃𝑝𝑜𝑝 × (1 +  𝑚𝑖) (2) 
 
where m was estimated for one of the dichotomic covariate values (e.g. males). 
Body weight was a priori included as a covariate using a power function with a fixed 
exponent of 0.75 on clearance and 1 on volume parameters. Furthermore, as children below 
the age of 2 years were included, a Hill function based on postmenstrual age was tested to 
describe maturation on clearance (equation 3):  
 
𝐹𝑚𝑎𝑡 =  
𝑃𝑀𝐴𝐻𝐼𝐿𝐿
𝑇𝑀50
𝐻𝐼𝐿𝐿+𝑃𝑀𝐴𝐻𝐼𝐿𝐿
 (3) 
 
where Fmat represents the maturation function, PMA the postmenstrual age, Hill the Hill 
coefficient describing the steepness of the function, and TM50 the maturation half-life.
27 
The potential impact of remaining covariates was explored by visual inspection of post-
hoc individual PK parameter estimates and deviations from population-predicted PK 
 parameters (ETAs) versus covariate plots. Only clinically relevant associations were 
considered: gender, serum cystatin C, PELOD score, PRISM score, admission reason and co-
medication related covariates for clearance, and age, gender, PELOD score, PRISM score and 
admission reason for volumes of distribution. 
To account for the age effect in serum cystatin C values, data from Fischbach et al. and 
Randers et al. were used as reference (i.e. typical value) for each age (Tcystatin C). 
28,29 An 
exponential decline was found, according to following equation (equation 4): 
𝑇𝑐𝑦𝑠𝑡𝑎𝑡𝑖𝑛 𝐶 =  1.598 × 𝑒
−0.624 ×𝑎𝑔𝑒  (𝑦𝑒𝑎𝑟𝑠) (4) 
 
Above the age of 1.3 years, a typical constant value of 0.8 mg/L was used. 
Possible influence of serum cystatin C on clearance was subsequently evaluated using 
measured serum cystatin C values (Mcystatin C ) and according to following equation (equation 
5): 
(
𝑀𝑐𝑦𝑠𝑡𝑎𝑡𝑖𝑛 𝐶 
𝑇𝑐𝑦𝑠𝑡𝑎𝑡𝑖𝑛 𝐶 
)
𝑛
(5) 
 
Scr could not be evaluated as potential covariates on clearance, given 39% of Scr 
samples were below quantification limit (BQL). Selected covariates were then separately 
entered into the model and evaluated by use of OFV via forward inclusion (p<0.05) and 
backwards elimination methods (p<0.001). In addition, a clinically relevant reduction in the 
magnitude of BSV on the parameter of interest, acceptable precision of the model parameters, 
and visual inspection of the goodness-of-fit plots were used to support the additional inclusion 
of additional covariates into the model. 
 
Model evaluation 
 Model performance, stability and robustness were evaluated using a nonparametric bootstrap 
analysis (n=1000 samples), a prediction-corrected visual predictive check (pcVPC) stratified 
for weight (n=1000 simulations), and the normalised prediction distribution error (NPDE) 
(n=1000 simulations).30,31  
PTA simulation analysis  
Monte Carlo simulations were performed to simulate piperacillin and tazobactam exposures 
for 3500 patients (Table 1).22,32 The simulation dataset was created using a function described 
by Sumpter et al., in order to simulate weights based on postmenstrual age and sex, evenly 
distributed within the age range of our patient population (n=250 boys and 250 girls each, for 
the age categories 1 to 6 monts, 6 months to 1 year, 1 to 2 years, 2 to 4 years, 4 to 8 years, 8 to 
12 years, 12 to 15 years).33  
Based on these simulations, fT>MIC and fT>CT were calculated for the first 48 hours of 
treatment, as early and appropriate therapy is most critical.34 The target efficacy exposure for 
piperacillin was defined as 60% fT>MIC and PTA was calculated for MICs between 1 to 64 
mg/L.16 A PTA ≥ 90% was defined as optimal. To evaluate proposed dosing regimens, an 
infection with Pseudomonas aeruginosa and MIC of 16 mg/L was used, according to the 
EUCAST breakpoint for piperacillin.35 For tazobactam, the reference target efficacy exposure 
values included 40, 60 and 80% fT>CT and PTA was calculated for CTs between 0.25 and 8 
mg/L. Given that tazobactam is given in a fixed combination with piperacillin (ratio 8:1), only 
those dosing regimens with a PTA≥90% for piperacillin were appraised (Table 1). Mean 
protein binding of piperacillin and tazobactam is 30%, and this was used to simulate unbound 
concentrations.36 
 
RESULTS 
 A total of 47 patients were included; demographic, clinical and treatment characteristics are 
summarized in Table 2. Patients younger than 2 years accounted for 42.5% of the study 
population (n=20). Of a total of 317 piperacillin and 125 tazobactam plasma samples collected, 
7 piperacillin (2%) and 4 tazobactam (3%) concentrations were excluded from pharmacokinetic 
analysis due to sampling errors. Median number of samples available for analysis per patient 
was 7 for piperacillin and 6 for tazobactam. 
A two-compartment model with first-order elimination best described the data of both 
piperacillin and tazobactam. BSV for piperacillin and tazobactam was described using an 
exponential model and was identified on clearance and all volume parameters. A proportional 
error model was used to describe residual variability for both compounds. Neither saturable 
elimination nor IOV on clearance and volume of distribution was identified on piperacillin. 
BSV on the central volume of distribution of the piperacillin compound was estimated to be 
close to a value of 0 after inclusion of allometric scaling. No significant change in OFV was 
noted when it was fixed to 0 for subsequent model building steps. Implementation of a 
concomitant vancomycin treatment covariate on piperacillin clearance resulted in a drop in 
OFV of 18.57 points with a marginal decrease of BSV on clearance. With only six individuals 
receiving vancomycin, and a potential confounding by age differences between those who 
received vancomycin and those who did not (median age [range] 4.71 [3.08-11.92] years, 
versus 2.17 [0.17-15] years), this covariate was not included in the final model. In addition, the 
more parsimonious final model incorporating weight and PMA as described above performed 
reasonably well, with only slight deviations in the higher concentration range (Figure 1A-B). 
No other collected clinical variables were deemed necessary for further statistical covariate 
testing, based on visual inspection of the covariate plots.  
The final covariate equations, population PK parameter estimates and their precision 
are summarized in Table 3. All structural model parameters were estimated with adequate 
 precision, which was further confirmed with the bootstrap analysis. The pcVPC plots are 
presented in Figure 2; the 5th, 50th and 95th percentiles of the predicted concentrations closely 
follow the percentiles of the observed data, suggesting a good model fit in both cases. The 
NPDE mean and variance were not significantly different from 0 and 1, respectively (p>0.1) 
(Figure not shown). 
The PTA for piperacillin by MIC after 48h of treatment for different dosing scenarios 
(Table 1) are presented in Figure 3 (intermittent dosing) and Figure 4 (continuous dosing 
regimens). With a MIC value of 16 mg/L, PTA for intermittent dosing regimens ranged from 
5.9% (75 mg/kg piperacillin every 8 h, 15 min infusion) to 99% (100 mg/kg piperacillin every 
4 h, 2 hour infusion). Three intermittent dosing regimens met the PTA criterion of 90% (75 
mg/kg piperacillin every 4 h, infusion over 2 h; 100 mg/kg every 4 h over 1-2 h). For all 
continuous dosing regimens, PTA was 100% for the time after the loading dose. 
PTA for tazobactam by CT after 48h of treatment are presented in Figure S1 (selection 
of intermittent dosing regimens with PTA>90% for piperacillin) and Figure S2 (continuous 
dosing regimens). For a CT below 2 mg/L, PTA was >90% for all selected intermittent dosing 
scenarios, regardless of the target fT>CT (12.5 mg/kg tazobactam every 4h, 1-2h infusion, 9.375 
mg/kg every 4h, 2h infusion). For all continuous dosing regimens, PTA for a CT of 4 mg/L was 
100% for the time after the loading dose, regardless of the target fT>CT.  
 
DISCUSSION 
This is, to our knowledge, the largest study to date in which the pharmacokinetics of 
piperacillin and tazobactam has been characterized in critically ill infants and children (n=47). 
This is also the first time that pharmacokinetic data have been collected in children between 
the ages of 2 months and 1 year (n=14) and 9 and 15 years (n=10).   
 Of note is the fact that we have characterized the effect of growth and organ maturation 
on the pharmacokinetics of both compounds, as demonstrated by the functions describing the 
clearance of both piperacillin and tazobactam. A similar model describing the effect of organ 
maturation was proposed by Tornoe et al., who analysed pooled data from hospitalized children 
with a suspected or proven infection, and Rhodin et al., who described the maturation on 
glomerular filtration rate.37,38 The maturation half-life, which is the age associated with 50% 
maturation of clearance, and the age associated with full maturation in our study were 5.5 
months and 4.8 years, respectively (Table 3). These estimates were significantly lower than 
previously reported by the forementioned authors, (maturation half-life: 2.2 months; full 
maturation around 2 years of age) and suggest that critical illness could cause a (temporary) 
impairment of the underlying renal maturation process.37,38   
When comparing the maturation parameter estimates of piperacillin versus tazobactam 
in our population, it seems that maturation of tazobactam clearance was less affected when 
compared to piperacillin clearance, with a maturation half-life and age of full-maturation closer 
to Tornoe and Rhodin estimates.37,38 Although more data from neonates and infants are needed 
to estimate maturation more accurately, these observations raise questions about the impact of 
fixed-dose combinations of piperacillin/tazobactam in seriously ill young children.  
Since both compounds are renally cleared, one cannot exclude the role of organ function on 
the elimination of either compound. Hence, while the relationship between markers of renal 
function is plausible and expected, variations in drug clearances in this group of patients were 
captured primarily by body weight and the maturation function, which is in agreement with 
findings from previous studies in critically ill children.14,15  
Cystatin C is a low molecular weight protein which is completely filtered through the 
glomeruli, rendering it a promising biomarker for measuring Glomerular Filtration Rate (GFR) 
in children. Recently, it was found to predict elimination of the renally cleared 
 amoxicillin/clavulanic acid with a similar covariate model as ours, in a comparable population 
PK study in critically ill children (n=50 patients).39 One could only speculate why, in this study, 
we were not able to identify cystatin C as a drug clearance descriptor. Potential explanations 
include (i) serum cystatin C may be affected by the underlying disease (septic conditions), 
which may mask the effect of age on organ function (i.e., GFR),  (ii) too narrow variation in 
cystatin levels to identify a statistically significant correlation, since no patients with renal 
insufficiency were included, (iii) both compounds are cleared substantially more through 
tubular secretion (besides glomerular filtration), when compared to amoxicillin/clavulanic 
acid. As mentioned previously, we were not able to evaluate serum creatinine (and estimated 
glomerular filtration rate based on serum creatinine) as a potential covariate due to the large 
portion of BQL values. In this study, the Jaffe reaction was used for creatinine bio-analysis, a 
method which is still very popular due to its simplicity and low cost. Due to a standardisation 
of creatinine measurements in 2006, analyzers automatically now correct through the use of a 
fixed correction factor to adjust for interfering protein content in adults. Unfortunately, due to 
lower total protein reference ranges, this overcorrection can potentially lead to undetectable 
creatinine levels in infants and children.40 No further clinically relevant covariates on PK 
parameters were found. 
As β-lactam antibiotics are time-dependent antibiotics with fT>MIC the PK/PD parameter 
of interest, drug clearance is the most important  PK parameter related with adequate exposure. 
The observed population estimate for piperacillin clearance (0.25 L/h/kg) is within the 
observed range in 47 non-ICU children (0.20-0.35 L/h/kg) and comparable to what has been 
observed in 16 critically ill adults with hyperfiltration (0.25 L/h/kg).7,41 It is noticeably higher 
(>20%) when compared to studies in neonates (0.08-0.14 L/h/kg), non-ICU oncology children 
(0.20 L/h/kg), healthy adults (0.14-0.16 L/h/kg), and a cohort of 12 critically ill children (0.20 
L/h/kg), but substantially lower (>20%) than observed in another cohort of 13 critically ill 
 children (0.30 L/h/kg).10,11,13-15,42 The observed tazobactam clearance (0.13 L/h/kg) is lower to 
what has previously been observed in children of the same age.7,15 Despite the limitations for 
a direct comparison of the results, disease-driven changes in drug disposition can have major 
impact on drug clearance. In several subpopulations of critically ill adults, augmented renal 
clearance (ARC) of antibiotics leading to subtherapeutic concentrations has been extensively 
described.43 Despite increasing appreciation of this phenomenon, scarce data are available in 
children receiving β-lactam antibiotics.14,40,44  
In our study population clearance values higher than expected were observed in some 
patients with observed individual piperacillin clearances up to 0.35 L/h/kg. We hypothesize 
that such an apparent variation in clearance results from an increase in renal blood flow, leading 
to hyperfiltration in those patients with sepsis. The hypothesis of ARC was also supported by 
the fact that a large proportion of measured renal biomarkers was undetectable (Scr) or low 
(CysC) compared to age-corrected reference values.45 A plausible explanation, besides the 
analytical challenges for creatinine described above, could be a faster renal clearance of these 
endogenous compounds. Moreover, trough concentrations from maintenance doses remained 
very low in most patients. This phenomenon suggests that no accumulation occurs during 
steady-state conditions, probably due to the enhanced renal capacity. Although our study was 
not powered for the evaluation of efficacy, we speculate that children admitted to the ICU with 
lower disease severity and organ failure scores are most at risk for ARC and subsequent 
subtherapeutic antibiotic concentrations, as previously observed in adults.41 Notably, children 
admitted to a general paediatric ward, may also experience ARC since high piperacillin 
clearances (upper range of 0.35 L/h/kg) have also been reported in non-ICU children with 
suspected or proven infection.7 Further investigation is needed to identify patient risk factors 
for developing hyperfiltration in children. 
 Regarding the observed population estimate of volume of distribution for piperacillin 
(0.25 L/kg), our observation is within the observed range in non-ICU children (0.24-0.33 L/kg). 
It is noticeably higher (>20%) when compared to healthy adults (0.14-0.18 L/kg) but 
substantially lower than reported in (pre-)term neonates (0.37-0.42 L/kg), non-ICU oncology 
children (0.41 L/kg, two other studies in critically ill children (0.43-0.55 L/kg) and critically 
ill adults (0.35 L/kg).7,11-15,41 The observed volume of distribution of tazobactam (0.24 L/kg) is 
lower to what has previously been observed in children of the same age (0.30-0.39 L/kg).7,15  
Also here, it is unclear whether these differences in volume of distribution are due to 
differences in body composition of the study population (e.g. larger total and extracellular body 
water content in neonates compared to infants and children), differences in disease severity 
(e.g. vascular leakage), and/or different sampling and PK parameter estimation methods.  
Treating infections in the seriously ill child without evidence-based dosing 
recommendations remains a huge challenge and may lead to an increased morbidity and 
mortality.46 Our analysis challenges currently used dosing regimens (75-100 mg/kg piperacillin 
every 6 to 8 hours, given as a short infusion), as they only yield a PTA between 5.9 to 34% for 
piperacillin, thereby potentially leading to subtherapeutic treatment (Figure 3).14 These 
findings of underdosing are consistent with previously reported exposure data in critically ill 
children of the same age.14,15  
For the treatment of Pseudomonas infections, no clear-cut fT>CT target values are 
available for tazobactam, in combination with piperacillin. Therefore, we performed a PTA 
analysis appraising different targets (20-60-80% fT>CT) (Figure S1, S2). The choice was based 
on the only properly designed in vitro study in which the pharmacodynamics of tazobactam 
was characterised in combination with piperacillin.5 Further studies are required to confirm the 
appropriate target. Our analysis should be interpreted with caution, but it does provide insight 
into how differences in exposure may affect antimicrobial response. 
 More frequent dosing, prolonged infusions and continuous infusions have been 
proposed as dose optimization strategies for β-lactam antibiotic treatment.47 However, it should 
be noted that, we have specifically chosen not to select higher amounts per dose for intermittent 
dosing regimens (max. 100/12.5 mg per kg piperacillin/tazobactam) than currently 
recommended. This was done to mitigate potential safety risks related to higher peak 
concentrations, thereby avoiding the potential for saturation of the elimination processes which 
determine the clearance of piperacillin. This ‘same amount per dose’ approach should also 
prevent a higher degree of reduced tazobactam clearance, as it is known that both piperacillin 
and tazobactam interact by a competitive inhibition at the level of the tubular anion transporter 
system.48 Regarding the safety of continuous infusions, Delvallée et al. reported the use of a 
400 mg/kg/day infusion on a paediatric haematology unit without any observed adverse 
events.44  
Our simulations showed that, four hourly dosing regimens (given as a prolonged 
infusion), and all continuous dosing regimens met the PTA criterion for piperacillin (Figure 
3,4). Despite the higher PTA with these prolonged and continuous infusions, we acknowledge 
that these dosing regimens may have important implications on drug administration practices, 
as intravascular access is frequently limited and drug incompatibilities with 
piperacillin/tazobactam often occur.47,49 Therefore, a rational choice in dosing regimen is 
advised, depending on the individual patient characteristics, site of infection and target MIC. 
In our opinion, prolonged and continuous infusions seem a preferable option whenever 
possible, especially when antibiotic therapy is started empirically or when higher fT>MIC targets 
are needed (e.g. neutropenic children). 
This research has some notable limitations. First, the studied population included a 
heterogeneous group of children with regard to possible differences in (suspected) infecting 
organism and tissue involvement/penetration. Second, total drug plasma concentrations were 
 mathematically corrected for protein binding instead of free drug concentration measurement 
in plasma, or drug measurement at the site of infection. However, this simplification was 
previously found to be acceptable for β-lactam antibiotics with low protein binding like 
piperacillin and tazobactam.50 Third, MIC values were not prospectively determined in order 
to be able to calculate individual target drug concentrations in culture-proven infections. 
Instead, a worst-case scenario using the clinical breakpoints for P. aeruginosa was chosen as 
reference to explore dosing regimens by fT>CT. This approach is suitable for β-lactam 
antibiotics and tazobactam, which are known to have a wide therapeutic index. Consequently, 
there should be limited concern about potentially supra-therapeutic dosing. Moreover, from 
our simulation studies, we concluded that there is no risk for accumulation of piperacillin and 
tazobactam, when using any of the alternative dosing scenarios (Table 2). Fourth, 
notwithstanding that a substantial number of younger patients were recruited, more extensive 
PK data from neonates and infants are needed to estimate maturation parameters more precisely 
on both clearances and refine dosing regimens in these age categories.  
In conclusion, our study shows that current dosing recommendations for piperacillin 
and tazobactam can result in subtherapeutic treatment in critically ill children, thereby risking 
treatment failure. We proposed alternative, model-based dosing regimens that increase the PTA 
from 5.9 to 100 % for P. aeruginosa infections with a MIC of 16. A prospective, randomized 
controlled trial evaluating efficacy and safety for the proposed optimized dosing strategies may 
be required to further substantiate these results.   
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Table 1. Simulated dosing scenarios 
Intermittent dosing regimena Infusion duration 
 75 mg/kg every 4 hours 0.25, 0.5, 1, 2 hour(s) 
 75 mg/kg every 6 hours 0.25, 0.5, 1, 2 hour(s) 
 75 mg/kg every 8 hours 0.25, 0.5, 1, 2 hour(s) 
 100 mg/kg every 4 hours 0.25, 0.5, 1, 2 hour(s) 
  100 mg/kg every 6 hours 0.25, 0.5, 1, 2 hour(s) 
 100 mg/kg every 8 hours 0.25, 0.5, 1, 2 hour(s) 
Continuous infusion dosing regimena  
 LD of 75 mg/kg over 1 hour, followed by CI 300 mg/kg over 24 hours 
 LD of 75 mg/kg over 1 hour, followed by CI 350 mg/kg over 24 hours 
 LD of 75 mg/kg over 1 hour, followed by CI 400 mg/kg over 24 hours 
abased on piperacillin component and a fixed ratio of piperacillin:tazobactam of 8:1 
Abbreviations: LD: loading dose; CI: continuous infusion 
 
 
  
 
 
 
 
 
 
 
 
 
Table 2. Demographic and clinical characteristics of the study population 
Variablea Median (range) 
Gender  
 Male 21 (44.7%) 
 female 26 (55.3%) 
Age (years) 2.83 (0.17-15) 
Weight (kg) 14 (3.40-45) 
PRISM II score 8 (0-40) 
Primary reason for ICU admission  
 respiratory 11 (23.4) 
 gastro-intestinal 10 (21.3) 
 neurologic  7 (14.9) 
 postoperative  7 (14.9) 
 cardiovascular  7 (14.9) 
 burn 2 (4.3) 
 oncology 1 (2) 
 other 2 (4.3) 
Mechanical ventilationc 25 (53.2) 
Vasopressor treatmentc 15 (31.9) 
PELOD scored 1 (0-32) 
Serum Creatinine (mg/dL)d,e    0.21(<0.17-0.55) 
Plasma Cystatin Cd,e (mg/L) 0.66 (0.38-1.13) 
Serum CRPf (mg/L) 7.8 (0.1-147) 
 aAbbreviations: PRISM, Pediatric Risk of Mortality; PELOD, Pediatric 
Logistic Organ Dysfunction; CRP, C-Reactive Protein 
 cduring ICU stay; dat day(s) of sampling; e below quantification limit in 
14 patients;  fbased on values from 44 patients. 
 
 
 
 
 
 
 
Table 3. Population Pharmacokinetic Estimates of Piperacillin/tazobactam 
 
 Piperacillin Tazobactam 
 Estimate RSE (%) Bootstrap estimates (n=1000)a Estimate RSE (%) Bootstrap estimates (n=1000)a 
 
  Median  
 
Percentile 
2.5% 
 
97.5% 
  Median  
 
Percentile 
2.5% 
 
97.5% 
 Structural model parameters 
 
𝐶𝐿𝑖 = 𝐶𝐿𝑝𝑜𝑝 ×  (
𝑊𝑇
14
)
0.75
×  (𝑃𝑀𝐴𝐻𝐼𝐿𝐿 𝑇𝑀50
𝐻𝐼𝐿𝐿⁄ + 𝑃𝑀𝐴𝐻𝐼𝐿𝐿) 
 CL(L/h) 4.00 (0.25)b 8 4.04 3.50 5.50 3.01 (0.13)b 5 3.01 2.72 3.33 
 TM50 (weeks) 61.2 15 62.5 46.2 126 41.2 11 41.7 33.6 51.31 
 Hill coefficient 1.62 27 1.60 0.74 2.84 2.96 31 3.10 1.41 14.3 
 
𝑄𝑖 = 𝑄𝑝𝑜𝑝 ×  (
𝑊𝑇
14
)
0.75
 
 Q (L/h) 2.72 (0.19)b 14 2.68 2.06 3.78 2.11 (0.15)b 28 2.18 1.34 6.64 
 
𝑉𝑖 = 𝑉𝑝𝑜𝑝 ×  (
𝑊𝑇
14
)
1
 
 V1 (L) 1.80 (0.13)b 5 1.80 1.63 1.99 1.86 (0.13)b 12 1.82 1.19 2.15 
 V2 (L) 1.59 (0.11)b 9 1.58 1.35 1.92 1.58 (0.11)b 16 1.59 1.19 2.51 
 Between-subject variability 
 BSV CL (% CV) 26.7 25 25.5 18.5 31.3 14.5 29 11.7 3.92 19.8 
  
 
 
 
 
 
Figure 1A. Goodness-of-fit diagnostic plots for piperacillin: observations versus population 
predictions and individual predictions and conditional weighted residuals (CWRES) versus 
time after dose and population predictions.  
 
 
 
 
 
 
 
 
 
 
 
 BSV V1 (% CV) 0d - - - - 41.1 14 41.0 21.4 57.6 
 BSV Q (% CV) 0d - - - - 0d  - - - - 
 BSV V2 (% CV) 22.6 72 22.9 8.42 37.8 27 21 26.1 12.9 36.5 
 Residual variability 
 Proportional (% CV) 31.0 14 30.5 26.5 34.6 30.5 20 30.2 24.0 36.6 
 Additive (mg/L) 0.0001c  - - - - 0.0001c - - - - 
anon-parametric bootstrap: 969 runs mimization successful for piperacillin; 850 runs minimization succesful for tazobactam;bparameters per kg body weight; cfixed value  
Abbreviations: CLi, individual clearance; CLpop, population clearance; WTmed, median weight; PMA, postmenstrual age; TM50, maturation half-life; Hill, Hill coefficient; Q, 
intercompartmental clearance; BSV, between-subject variability; RSE, relative standard error 
  
 
 
 
 
 
 
 
 
 
Figure 1B. Goodness-of-fit diagnostic plots for tazobactam: observations versus population 
predictions and individual predictions and conditional weighted residuals (CWRES) versus 
time after dose and population predictions.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2. Prediction-corrected visual predictive check (n= 1000 simulations) for piperacillin 
(left panel) and tazobactam (right panel): grey shaded areas are 95% confidence intervals of 
simulated 5th, 50th and 95th percentiles, lines are 5th, 50th and 95th percentiles of raw data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3. PTA  for piperacillin (n=3500 patients) according to following intermittent dosing 
regimens : (A) 75 mg/kg every 4, 6, 8 hours or 100 mg/kg every 4, 6, 8 hours over 0.25 hours, 
(B) 75 mg/kg or 100 mg/kg every 4, 6, 8 hours over 0.5 hour, (C) 75 mg/kg or 100 mg/kg every 
4, 6, 8 hours over 1 hour, (D) 75 mg/kg or 100 mg/kg every 4, 6, 8 hours over 2 hours. 
Piperacillin target was defined as 50% of time above a MIC of 16 mg/L. The solid horizontal 
line represents 90%. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4. PTA for piperacillin (n=3500 patients) according to following continuous dosing 
regimens : loading dose of 75 mg/kg over 1h, followed by (i) a continuous infusion (CI) of 300 
mg/kg/24h, (ii) CI of 350 mg/kg/24h, (iii) CI of 400 mg/kg/24h. Piperacillin target was defined 
as 50% of time above a MIC of 16 mg/L. The solid horizontal line represents 90%. 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
